# Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome

> **NCT00001596** · PHASE2 · COMPLETED · sponsor: **William Gahl, M.D.** · enrollment: 35 (actual)

## Conditions studied

- Albinism
- Inborn Errors of Metabolism
- Oculocutaneous Albinism
- Platelet Storage Pool Deficiency
- Pulmonary Fibrosis

## Interventions

- **DRUG:** Pirfenidone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00001596
- **Lead sponsor:** William Gahl, M.D.
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2009-09
- **Final completion:** 2016-05-09
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001596, "Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00001596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*